Business
Suspension of Trading Pending 2022 Annual Report
Suspension of Trading Pending 2022 Annual Report.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n \n2 May 2023\n \nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nSuspension of Trading Pending 2022 Annual Report\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, provides the following update in relation to the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2022 (the \"2022 Annual Report\").\nIn accordance with the listing rules, the Company was required to publish its audited 2022 Annual Report by 30 April 2023; however, due to the late appointment of BDO LLP as the Company's new auditors in January 2023, BDO LLP have requested additional time in order to complete their audit work. While the audit process has yet to be concluded, the Directors have been advised by the auditors that the audit is substantially complete and accordingly, the Company is targeting the publication of the 2022 Annual Report as soon as the auditor completes their work, which is expected to be completed shortly.\nAs a result of the delay in publishing the 2022 Annual Report, the Company's shares will be temporarily suspended from the Official List and from trading on the London Stock Exchange with effect from 7.30am today. Following the publication of the 2022 Annual Report the Company will make application for the suspension to be lifted.\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO. 596/2014, AS RETAINED AND APPLICABLE IN THE UK PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (\"MAR\"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \n-ENDS-\nEnquiries:\n\n\n\nRoquefort Therapeutics plc\n\n\n\n\nStephen West (Chairman) / Ajan Reginald (CEO)\n\n\n+44 (0)20 3290 9339\n \n\n\n\n\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\n \nOptiva Securities Limited (Joint Broker)\n\n\n \n+44 (0)203 764 2341\n\n\n\n\nChristian Dennis\n \nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n \n\n\n+44 (0)20 3411 1881\n \n \n+44 (0)20 7466 5000\n \n\n\n\n \nLEI: 254900P4SISIWOR9RH34\n \nAbout Roquefort Therapeutic...